logo
Share SHARE
FONT-SIZE Plus   Neg

Regenersis To Acquire Blancco In EUR 60 Mln Deal - Quick Facts

Regenersis plc (RGS.L), an outsourcing partner to the global consumer technology companies, Monday announced it has conditionally agreed to acquire all of the issued share capital of Blancco Oy Ltd, a provider of data erasure software, and controlling stakes in its major sales offices for about 60 million euros.

Of the total consideration, 58.7 million euros will be in cash and about 1.3 million euros will be in shares

To fund the acquisition, as well as for general corporate purposes, the company has conditionally raised gross proceeds of 100 million pounds through a placing of 28,986,000 new ordinary shares of 2 pence each, at a price of 345 pence per share, with new and existing institutional shareholders Panmure Gordon (UK) Ltd.and Cenkos Securities plc. Regenersis said the placing was significantly oversubscribed.

The company noted that holders of the new ordinary shares will not be entitled to receive the interim dividend of 1.32 pence per share payable for the 6-month period ended December 31, 2013.

The company expects that in the wake of the approval of the draft European General Protection Regulation by European Parliament, due to come into force in 2015, there will be a higher compliance burden on companies holding consumer data, both in terms of processes and in terms of documentation and record keeping requirements as well as a new requirement for some companies to have a permanent data protection officer.

"I am delighted with this acquisition. Blancco is a great business with an excellent fit, and at a price that works for shareholders. Most importantly it moves the centre of gravity of the group clearly into Advanced Solutions, with a majority of our profits in this segment, and it opens up a variety of possibilities for future development," said Matthew Peacock, Executive Chairman of Regenersis.

The acquisition is expected to be completed on April 17.

The company also said its expects profit growth in the second half of the financial year ended June 30, 2014 will come mainly from the Emerging Markets and Advanced Solutions divisions.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT